Octreotide controlled release - Camurus
Alternative Names: CAM-2029; OclaizTM; Octreotide chloride controlled release; Octreotide subcutaneous (SC) depot - CamurusLatest Information Update: 18 Jul 2024
At a glance
- Originator Camurus
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Acromegaly
- Phase III Neuroendocrine tumours
- Phase II/III Polycystic liver disease
- Phase II Adult respiratory distress syndrome
Most Recent Events
- 15 Jul 2024 FDA assigns PDUFA action date of (21/10/2024) for octreotide controlled release for Acromegaly
- 15 Jul 2024 Safety and efficacy data from the phase III ACROINNOVA 2 trials in Acromegaly released by Camurus
- 23 May 2024 European Medicines Agency accepts MAA for Octreotide controlled release for Acromegaly for review